Background Prisons are important settings for blood-borne virus control because of the high prevalence of hepatitis C and B viral infections (HCV and HBV), and behaviours associated with transmission among prisoners. Conclusions Although hepatitis testing has increased, only a small proportion of the prison population were tested. More testing is required to identify infected prisoners and refer them for appropriate treatment.
Background
Hepatitis C and B viral infections (HCV/HBV) cause considerable morbidity and are costly to the National Health Service. 1, 2 Prisons are important settings for blood-borne virus (BBV) prevention and control because the prevalence of HCV and HBV is high among prisoners and risk behaviours associated with transmission are practised. 3, 4 In England and Wales, the prevalence of anti-HCV and antihepatitis B core antigen (HBc) among prisoners in the late 1990s was 7 and 8%, respectively. 3 Prisons provide an opportunity to reach injecting drug users (IDUs), 5, 6 a highrisk group for HCV and HBV, as current and former IDUs make up a significant proportion of the prison population. 7 Increasing preventative efforts to reduce the spread of HCV through raising awareness and increasing HCV diagnostic testing in prisons have been recommended. 2, 8 In 1996, the Department of Health (DH) recommended that all eligible individuals entering prison should be offered hepatitis B vaccine. 6 Testing prisoners for HCV and HBV could reduce incidence, by identifying and treating infected persons, with consequent reductions in transmission, morbidity and mortality. population, to offer both testing and treatment, therefore monitoring HCV and HBV testing is essential. Data from Health Protection Agency's (HPA) sentinel surveillance of hepatitis testing, which collects data on hepatitis testing from 24 sentinel laboratories in England, 11, 12 will be used to investigate anti-HCV, hepatitis B surface antigen (HBsAg) and anti-HBc testing in English prisons between 2005 and 2008 . This paper will describe the characteristics of prisoners tested and associated risk factors for anti-HCV positivity, trends in testing over time and estimate the proportion of the prison population tested.
Methods Participants and data collection
The methods of the sentinel surveillance study of hepatitis testing have been described elsewhere. 11 Test results and demographic information for individuals tested for hepatitis A, B or C in participating laboratories were extracted electronically from the laboratory information systems. Soundex coding 13 was applied to patient names that were removed and data from all sites merged.
Data handling
Data from the sentinel surveillance of hepatitis testing study was used to examine anti-HCV, HBsAg and anti-HBc testing in English prisons. Data were extracted for all individuals tested for anti-HCV (and HCV RNA for those who tested positive for anti-HCV) and/or HBsAg and/or anti-HBc between 1 January 2005 and 31 December 2008 inclusive, where prisons were the source of the first test request. Prisoners were identified using a unique unnamed reference number and linked to all related test results and demographic information. Age was calculated at the date of first test. IDUs were identified using a keyword search of the free text fields and questionnaire data (where available). Patient surname and first name (where available) were provided temporarily to apply Nam Pehchan software (#Bradford Health Authority and City of Bradford Metropolitan District council) to identify South Asian surnames, i.e. individuals with names originating in the Indian subcontinent.
14 Records where names were not available were excluded from analyses of ethnicity.
Prisons 
where i refers to prisoners vaccinated with at least one dose of hepatitis B vaccine within a month of being received into the prison establishment; ii refers to entrants to the prison establishment already vaccinated with three or more doses of the hepatitis B vaccine and iii refers to the number of prisoner received into the prison establishment within that month.
Reporting changed in November 2007; the denominator changed from being an average estimate to the actual number of prisoners received into the prison establishment each month along with their vaccination data. Prisons that reported vaccination and reception data were termed fully reporting prisons and those that reported vaccination data only were termed partially reporting prisons.
Statistical analysis
Data were stored in Microsoft Excel (2003) and analysed in SPSS (version 14.0). Differences in the proportion testing positive for anti-HCV and HBsAg were assessed using chi-squared tests. Relationships between categorical variables and anti-HCV or HBsAg status were investigated using univariable and multivariable logistic regression; largest groups were used as baseline. The multivariable model included sex, age, IDU status and region. The fit of the model was checked using a binomial model. Analyses of trends in testing and logistic regression were limited to prisons with full data for the 4 years.
The proportion of individuals tested for anti-HCV was estimated using prison population in custody data (Ministry of Justice, personal communication) as the denominator population for 24 prisons. The denominator included the number of people in custody on 31 December of that year and individuals entering prison thereafter as either remand, sentenced, fine-defaulters, non-criminals (held for civic offences) or transfers (between prison establishments). Data on transfers were only available for prisoners who were discharged. Length of stay was grouped into: incarcerated for more than 1 month, more than 2 months, more than 3 month, and more than 6 months. Length of stay was based on actual length of stay for those counted as transfers and sentence length for other prisoners.
A Wilcoxon signed-ranks test was used to test differences in the number of doses of hepatitis B vaccine delivered to prisoners between 2005 and 2008. 
Results
Data were available from 16 laboratories, performing testing for 39 prisons (30% of the prison estate; Table 1 ). All English regions except the West Midlands were covered. (Fig. 1 ). The majority of prisoners (8367/10 732, 78%) were tested for anti-HCV and HBsAg and/or anti-HBc (Fig. 1 ).
Half of prisoners tested were resident in local prisons (Table 1) . However, only a small proportion (1.8%) of the prison population was tested for anti-HCV in this setting. The proportion tested for anti-HCV was highest in female (7.1%) and high security establishments (7.4%) ( Table 1 ).
Hepatitis C
The majority (2413/9965, 24.2%) of prisoners tested for anti-HCV were aged 25 -34 years (Table 2) ; the mean age of those tested was 30.6 years (+SD 8.5). More males were tested than females.
Overall, 2413 (24.2%) people tested positive for anti-HCV. Of those prisoners who tested HCV positive, 1490 (62%) also had an HCV RNA test, of which 70% were RNA positive. The percentage of prisoners positive for anti-HCV was highest in the 35-44 year age group and declined thereafter (Table 2) . Females were 1.5 times more likely to test positive for anti-HCV than males (after adjusting for other variables). Prisoners aged 35-44 years were more likely to test positive than prisoners aged 25-34 years (Table 2) .
A higher proportion of prisoners reported to be IDUs were positive than those not reported to be IDUs (Table 2; x 2 ¼ 275.164, df ¼ 1, P , 0.001). Two-hundred (2%) questionnaires were received. Where a reason for test was reported, 'risk' was given for the majority (169/190, 88.9%). IDU was the most frequently reported risk exposure (180/ (Table 2) . Anti-HCV positivity varied regionally, lowest in the South East and highest in the North West (Table 2) . Prisoners in all regions were less likely to test positive for anti-HCV than those in the North West (Table 2) .
Hepatitis B
The majority of prisoners tested for anti-HBc were aged 25-34 years; the mean age of those tested was 30.4 years (SD + 8.3). Sixty-seven per cent of prisoners tested were male. Overall, 714 (13.9%) people tested positive for anti-HBc. Most prisoners tested for anti-HBc were also tested for HBsAg (4433/5151, 86.1%); 107 (2.4%) were HBsAg positive.
Hepatitis B vaccination monitoring programme
Data were available for 27 of the 39 prisons; on average 90% of these prisons reported every month (2005 -2008) . Over the 4 years, the number of doses delivered to prisoners increased by 25%, although this was not statistically significant (Wilcoxon signed rank test; Z ¼ 21.802, P ¼ 0.072). Vaccine coverage increased over the same period by 96% (Table 3) , although remained under 50% (fully reporting prisons only).
Coinfections
Of the 4104 prisoners tested for all three hepatitis markers, 342 (8.3%) were positive for both anti-HCV and anti-HBc and 37 (0.9%) were positive for anti-HCV and HBsAg. The majority of prisoners who were positive for both anti-HCV and HBsAg were male (n ¼ 33, 78.6%); just over half of the prisoners were aged 25-34 years; 1 (5%) was South Asian and 3 (8.1%) were reported to be IDUs. (Table 3 ). The proportion tested did not vary with assumptions about sentence length.
Trends in hepatitis B and C testing
Testing increased 35% for HBsAg (U ¼ 2.1, P ¼ 0.034) and 47% for anti-HCV (U ¼ 6.6, P , 0.001) between 2005 and 2008 (Table 3). While the proportion testing positive for anti-HCV decreased significantly from 26% in 2005 to 23% in 2008 (x 2 ¼ 9.966, df ¼ 3, P ¼ 0.030), no significant change was demonstrated for HBsAg.
Discussion
Main findings of the study Sentinel surveillance had confirmed that a large proportion of prisoners tested for hepatitis B and C in prisons were positive. It is reassuring that testing increased over the 4 years, in both the absolute number of tests and the estimated proportion tested. However, between 2005 and 2008, estimates suggest that only a small proportion (2.4%) of this prison population was tested with an estimated 311 000 prisoners not being tested for anti-HCV. Low levels of HCV testing could result in missed opportunities to diagnose and treat those individuals who are most at risk of HCV infection, IDUs, thus increasing the spread of this disease.
What is already known on this topic
The prevalence of anti-HCV in the English and Welsh prison population was 7% in 1997/98 and 31% among prisoners who were IDUs. 3 In the present study nearly a quarter of the prisoners tested were positive for anti-HCV. Although our study cannot determine prevalence, the proportion testing positive for anti-HCV is similar to the prevalence of anti-HCV in USA prisons (23.1%) and lower than the prevalence of anti-HCV in Australian prisons (37%). The high proportion of prisoners testing positive in the current study may suggest that people who are at risk of infection either requested or were targeted for testing. Evidence suggests that the prevalence of HCV among IDUs has increased in recent years. 17, 18 In 1997/98, the prevalence of anti-HBc was 8% in English prisoners. 3 In the present study, 14% of those tested for anti-HBc were positive. One Australian study showed that the prevalence of anti-HBc was 31% among prisoners. 16 Interestingly, at the time of the study HBV vaccination was only offered to prisoners if their sentence exceeded 6 months. Whereas, in the UK, all prisoners are offered HBV vaccination on entry into prison, 19, 20 In the present study, the majority of people tested for anti-HBc were also tested for HBsAg and few (2.4%) were HBsAg positive, which suggests that most prisoners testing positive for anti-HBc have evidence of past hepatitis B infection and few have acute infections. A new prevalence study of HCV and HBV infection in prisoners is required to establish the true prevalence of infection in English prisoners.
A survey conducted in 2004/05 estimated that over 90% of prisons offered some form of HCV and HBV testing 22 . However, less than half of these prisons routinely offered HCV testing and 50% routinely offered HBV testing. Currently information on the level of hepatitis C and B testing in English prisons is unknown.
What the study adds Anti-HCV testing has increased in the English population, 11 however, the number of people tested in prisons contributes a small proportion (1.5%) of HCV tests carried out in all health-care settings. 12 The proportion of prisoners testing positive for anti-HCV declined slightly between 2005 and 2008, but was less marked than the decline seen in other health settings; the latter was thought to be due to increased testing of lower risk groups. 12 Although, the framework for tackling BBVs in prison includes testing for HBV 21 there is no clear guidance on the cost-effectiveness of testing or testing strategy for HBV in prison. The data presented here suggest that in the absence of such guidance prisons are opportunistically testing inmates for HBV whilst testing for HCV.
Even when variations in the length of prisoner stay were taken into consideration, estimates suggest that ,3% of the total prison population in this study were tested. This finding is similar to a study conducted in 2004 that found 6.5% (range: 1.4-15.4%) of people in local prisons were tested for HCV. 18 The HCVAction Plan specifically identifies prisons as an institution where testing should be offered. The DH have developed and distributed targeted resources to inform prisoners of risks of transmission and harm minimization strategies in relation to BBVs and this may have contributed to the increase in testing demonstrated in this study over the 4 years. Qualitative research has described barriers to testing, such as lack of proactive approaches to offering testing, prisoners' fears and lack of knowledge about HCV, low motivation for testing and concerns about confidentiality and stigma, which may mean fewer people are tested. 22 More work is needed to increase the level of testing in prisons.
Although some prison types were poorly represented, the study has shown that the majority of testing was carried out in local prisons. Local prisons are a gateway for individuals when they enter the prison estate, which explains the high population in this setting and possibly why the proportion tested is low. Whilst training and female establishments have a similar population size relative to the number of prisons in each category, the proportion tested was higher in female prisons. This could be due to more female prisoners being identified as at risk of HCV or HBV infections 23 or better acceptance of testing. Similarly the prevalence of anti-HCV and anti-HBc, in England and Wales in the 1990s, was higher in convicted female prisoners (13% anti-HBc and 11% anti-HCV) when compared with convicted male prisoners (7.2% anti-HBc and 7.1% anti-HCV). 3 In the present study, females prisoners also had an increased risk of HCV, which is consistent with the literature, 24, 25 and the greater proportion of female prisoners charged with drug-related offences relative to males is commonly proposed to explain the sex differential. 25 While hard-to-reach groups can be targeted in prisons, those in custody for short periods of time can be hard to reach. This is particularly challenging for local prisons where population turnover is highest. Notwithstanding, the amount of testing occurring in local prisons is encouraging and this should encourage other prison types, with smaller populations, to step-up testing. Hepatitis B immunization, using the super accelerated schedule (a dose at 0, 7, 21days and a booster at 12 months), is recommended for all prisoners in the UK and should not be delayed whilst awaiting test results. 26 Vaccine coverage was moderate at ,50% and was calculated for fully reporting prisons and therefore coverage may be slightly under-or over-estimated. The increase in the number of vaccine doses delivered to prisoners between 2005 and 2008 suggests that vaccine coverage has increased, paralleling findings from studies which report an increase in vaccine uptake among IDUs in recent years.
5,27
Limitations of the study
The study has some limitations. This study focuses on English prisons and the results may not represent all prison systems. It was not designed to assess the reason for testing, test history or test offer. Data from the few questionnaires received identified that a risk factor, predominantly IDU, was the main reason for testing. More work is required to investigate this. Risk factors are poorly reported in routine laboratory data in sentinel surveillance 13 ; therefore IDU status was unknown for the majority of individuals tested. Denominator data on the prison population were challenging to obtain. The turnover of inmates in prison can vary depending on the type of prison establishment. Therefore, the estimates of the number of prisoners tested take into account the length of a prisoner's stay assuming that the prisoners were tested after a certain period of incarceration. Data on transfers were only available for individuals who were discharged in that year, which could lead to an underestimated prison population size. Apart from transfers, data on the length of stay was based on sentence length, which assumes that individuals completed their full sentence. Our study could not estimate the percentage of the prison population who were offered a test for anti-HCV which is likely to be higher than those tested. Factors affecting test uptake and test offer should be investigated in order to increase HCV testing. Data on the number of HCV tests offered to prisoners will be recorded as part of the 2010 Prison Health Performance and Quality Indicators (PHPQI) (see DH http:// www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_097118). Approximately 30% of the prison estate was represented in this study; testing may be different in other prisons not included here. Despite these limitations, the study has strengths which include the large coverage of the prison estate, hepatitis testing data were obtained from part of an ongoing study and were collected in the same way from each laboratory. This is also the first study to estimate the proportion of the prison population tested for anti-HCV in English prisons.
Conclusions
Testing for HBV and HCV in prisons has increased but only a small proportion of the prison population was tested. Although there is clear guidance on testing for HCV 2, 28 there is no such guidance for HBV. Considering the significant number of IDUs in the prison system and the proportion of prisoners testing positive for HBsAg and anti-HCV is high, health services in prison need to be improved for greater public health gains. Further increases in testing of prisoners are recommended and this is supported by a new PHPQI focusing on hepatitis C care pathways in prison. Health promotion resources should continue to be used to raise awareness of BBVs among offenders.
Supplementary data
Supplementary data are available at the Journal of Public Health online.
